Transcript Document

Training in Pharmaceutical Medicine –
the role of the Regulator
Training in Pharmaceutical Medicine –
the role of the Regulator
Dr John Jenkins
Chair, GMC Postgraduate Board
24 May 2010
GMC’s purpose
‘to protect, promote and
maintain the health and
safety of the public by
ensuring proper standards in
the practice of medicine’
Four interlocking functions

Maintaining the register of those
doctors who can work in the UK

Setting the standards for doctors

Promoting high standards of
medical education

Dealing firmly and fairly with
doctors whose fitness to practise
is in doubt
The GMC’s role in medical education




Co-ordinating all stages of medical education
Promoting high standards
Previously covered undergraduate education
and the first year of training after graduation
Quality assuring delivery of standards and
outcomes: QABME and QAFP
Stages of medical education and training
GMC
Provisional
registration
Medical School
(4-6 years)
GMC
PMETB
Full
registration
F1 year
(1 year)
Certificate of
completion of
training (CCT)
F2 year
(1 year)
Specialty/G
P training
(3-8 years)
Specialist/
GP register
(to
retirement)
Specialty doctors
Specialty training
Specialty training
(3-8 years)




Medical royal colleges and faculties draw
up curricula for specialty (including GP)
training and assessments, which were
approved by PMETB
Competition for selection, training quality
managed by postgraduate deans
PMETB certified completion of training
which leads to entry on GMC GP or
specialist register and eligibility to work as
a consultant/ GP principal
PMETB quality assured specialist training
The problem
Sir John Tooke: Aspiring to Excellence, January
2008:
‘The regulation of medical education from
Undergraduate to CPD should be seamless but
the current structure…
 creates diseconomies
 fails to link registration, certification and
revalidation
 permits the development of different cultural
approaches’
The benefits
 Rationalisation and simplification of regulation: a
single authority for medical regulation from
medical school to end of career
 A single point of contact for key interests
 The opportunity to share best practice and
achieve improvements.
 An integrated approach to education and training
 Access to greater resources through a wider cost
base
 The complete integration with other regulatory
functions enabling a focus on the whole doctor at
key stages of the career pathway
The merger

PMETB and the GMC were already working
closely together. There is a high degree of
continuity

DH(E) is funding the merger – NOT trainees

‘Shifting the GMC centre of gravity’ – creation of a
Directorate solely focused on Education
GMC governance model
Council (24)
Undergraduate
Board
Postgraduate
Board
Continued Practice
Board
Executive
Patients and
the public
Doctors
NHS and other
healthcare
providers
Medical
schools and
medical Royal
Colleges.
Key
Interest
Groups
Governance: Postgraduate Board
External membership includes:





Academy of Medical Royal Colleges
BMA (Junior doctors and SAS doctors)
Conference of Postgraduate Medical Deans
PMETB (Chair and Chair of Assessment
Committee)
NHS Employers
Quality and Certification work

How trainees are assessed for
CCT/CESR/CEGPR certificates has transferred
to the GMC since April 2010

GMC has agreed to maintain 2010/2011 fees at
2009/2010 rates

National Surveys of Trainees and Trainers will
continue
 4th year for Trainees
 3rd year for Trainers
Training in
Pharmaceutical Medicine
Training in Pharmaceutical Medicine is:





Outside of the NHS
Within industry, policy, research
Unlike most medical training within the UK, as it is
not organised within the geographical Deanery
structure (but not unique - occupational medicine and
medical oncology)
Quality assured by GMC according to its Quality
Framework for specialty (including GP) training
Virtual deanery and faculty are accountable to GMC
and need to reflect the Standards for Deaneries.
Training must meet the Generic standards for
training
PM Virtual Deanery
Faculty of
Pharmaceutical
Medicine
Lead Dean
JRCPTB/SAC in Pharmaceutical
Medicine
GMC Quality Framework
QA/QM/QC of postgraduate medical education and
training
Quality
Assurance
Quality
Management
Quality Control
GMC
Postgraduate
Deaneries (e.g.
PM virtual deanery)
Local Education
Providers (e.g.
organisation
offering PM training)
Colleges/faculties/
associations
GMC Approval of Pharmaceutical Medicine
Includes:
 One programme
 Capacity to train 200 trainees
 96 training locations in UK and Europe
Retained via:
 Annual Deanery Report
 Visit to Deanery
Visit to Pharmaceutical Medicine
“Thematic QA is a term used to describe ways that
the GMC might work with colleges/faculties and
other organisations to explore, assure and develop
specialty including GP training beyond the
deanery confines” (2007 onwards)
GMC Quality Framework for specialty
including GP training (paragraphs 86 – 88)
Pharmaceutical medicine has been the first to
experience of thematic QA
Visit to Pharmaceutical Medicine



Thematic visit took place in December 2009
Pharmaceutical Medicine specialist amongst visitors
Considered QM at virtual deanery level and QC at
organisational level, sampling training at these locations:





AstraZeneca
Roche
Bayer Schering
Sanofi-Aventis
Boehringer
and training at small research firms and MHRA

Visit Report available at:
www.gmc-uk.org/Pharmaceutical_Medicine_
Visit_To_Deanery_Report_December_2009.pdf_31583
898.pdf
Revalidation
 Consultation running until 4th June ‘Revalidation:
The Way Ahead’ – covers four main themes:




How revalidation will work
What doctors, employers and contractors of
doctors’ services will need to do
Patient and public involvement in revalidation
How and when revalidation will work
 A significant change is that the current proposals
are based on a single revalidation process –
rather than the parallel processes of relicensing
and recertification that were previously proposed
Proposals – Responsible officer
Under the draft Responsible Officer regulations,
the Faculty of Pharmaceutical Medicine is one of
the designated organisations that will appoint a
Responsible Officer
In the longer term, some pharmaceutical
companies may also appoint Responsible Officers
Appraisal
 For doctors working in the pharmaceutical
industry, revalidation will be based on appraisal,
normally through the doctor’s employing
organisation
 Appraisal will be based on what doctors do in
practice; the specialty framework developed by
the Faculty will help doctors demonstrate that
they meet the standards relevant to their practice
 Appraisers will normally be a senior physician or
have had the appropriate training and experience
Timelines
 Pilots – 2009 and 2010
 Progressive roll out – 2011 onwards
 The shared aim is to put in place
arrangements that delivered necessary
assurance, but which to the maximum extent
possible build on valued systems already in
place and are sufficiently flexible to avoid
imposing unreasonable burdens
A Unique Opportunity
Regulating Medical Education
and Training: Policy Review
Lord Naren Patel




Personal regulation
Team based regulation
Workplace regulation
National regulation
To form conclusions on what is
an appropriate, modern
approach to the regulation of
education and training within an
independent framework of four
interlocking regulatory functions
and four regulatory layers
Conclusions




New editions of Tomorrow’s Doctors and
curricula for Foundation and Specialty training
Introduction of revalidation
Merger of the GMC and PMETB
A once in a lifetime opportunity to work
together to develop the continuum of medical
education and training as an essential element
of the protection and promotion of the safety
and quality of heath care throughout the UK,
with professionalism at its heart